Nicholas P. Anagnou
YOU?
Author Swipe
View article: m6A mRNA Methylation in Hematopoiesis: The Importance of Writing, Erasing, and Reading
m6A mRNA Methylation in Hematopoiesis: The Importance of Writing, Erasing, and Reading Open
Over recent years, epitranscriptomic research has provided a new layer of gene regulation during hematopoietic development and aberrant hematopoiesis. Among the 170 identified RNA chemical marks, N6-methyladenosine (m6A) is the most abunda…
View article: m<sup>6</sup>A mRNA Methylation in Hematopoiesis: The Importance of Writing, Erasing, and Reading
m<sup>6</sup>A mRNA Methylation in Hematopoiesis: The Importance of Writing, Erasing, and Reading Open
Over recent years, epitranscriptomic research has provided a new layer of gene regulation during hematopoietic development and aberrant hematopoiesis. Among the 170 identified RNA chemical marks, N6-methyladenosine (m6A) is the most abunda…
View article: Developing Oncolytic Viruses for the Treatment of Cervical Cancer
Developing Oncolytic Viruses for the Treatment of Cervical Cancer Open
Cervical cancer represents one of the most important malignancies among women worldwide. Current therapeutic approaches for cervical cancer are reported not only to be inadequate for metastatic cervical cancer, but are also considered as c…
View article: Supplementary Table S7 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S7 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S7. Logistic regression analysis to investigate the potential confounding effect of previous supplementary treatment in the classification score of the 106 peptide biomarker panel.
View article: Supplementary Table S5 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S5 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S5. List of all peptides that were included in the peptide biomarker panels for detecting primary and recurrent UBC. For primary UBC, 116 peptide biomarkers were employed and optimized in an SVM-based classifier, using …
View article: Supplementary Table S2 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S2 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S2. Clinical and demographical data for the urine samples (n= 636) from recurrent UBC patients, categorized in the discovery (n=425) and validation phase (n=211). The distribution of the patients which previously receiv…
View article: Data from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Data from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Purpose: Urothelial bladder cancer presents high recurrence rates, mandating continuous monitoring via invasive cystoscopy. The development of noninvasive tests for disease diagnosis and surveillance remains an unmet clinical need. …
View article: Supplementary Table S7 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S7 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S7. Logistic regression analysis to investigate the potential confounding effect of previous supplementary treatment in the classification score of the 106 peptide biomarker panel.
View article: Data from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Data from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Purpose: Urothelial bladder cancer presents high recurrence rates, mandating continuous monitoring via invasive cystoscopy. The development of noninvasive tests for disease diagnosis and surveillance remains an unmet clinical need. …
View article: Supplementary Table S5 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S5 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S5. List of all peptides that were included in the peptide biomarker panels for detecting primary and recurrent UBC. For primary UBC, 116 peptide biomarkers were employed and optimized in an SVM-based classifier, using …
View article: Supplementary Table S6 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S6 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S6. Multivariate analysis for investigating the comparative performance of the biomarker classifier and cytology for detecting recurrence. Of the 211 subjects that were included in the validation phase, voided urinary c…
View article: Supplementary Table S6 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S6 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S6. Multivariate analysis for investigating the comparative performance of the biomarker classifier and cytology for detecting recurrence. Of the 211 subjects that were included in the validation phase, voided urinary c…
View article: Supplementary Table S4 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S4 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S4. Table summarizing the significant biomarkers that were revealed after statistical analysis between recurrent UBC cases (n=109) and negative for recurrence controls (n=316), using Wilcoxon test. The significant bioma…
View article: Supplementary Table S1 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S1 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S1. Clinical and demographical data for the full list of 721 samples from patients with primary UBC, separated in 451 urine samples to be included in the discovery phase and 270 urine samples to be included in the valid…
View article: Supplementary Table S8 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S8 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S8. Correlation analysis of the 116 peptide biomarkers with disease stage and grade and performance of peptide classifiers in detecting NMIBC and MIBC.
View article: Supplementary Table S2 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S2 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S2. Clinical and demographical data for the urine samples (n= 636) from recurrent UBC patients, categorized in the discovery (n=425) and validation phase (n=211). The distribution of the patients which previously receiv…
View article: Supplementary Table S3 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S3 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S3. Shortlist of significant biomarkers, as derived based on statistical analysis between primary UBC cases (n=341) and urological controls (n=110) - including negative after cystoscopy samples, samples from patients wi…
View article: Supplementary Table S1 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S1 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S1. Clinical and demographical data for the full list of 721 samples from patients with primary UBC, separated in 451 urine samples to be included in the discovery phase and 270 urine samples to be included in the valid…
View article: Supplementary Table S3 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S3 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S3. Shortlist of significant biomarkers, as derived based on statistical analysis between primary UBC cases (n=341) and urological controls (n=110) - including negative after cystoscopy samples, samples from patients wi…
View article: Supplementary Table S8 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S8 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S8. Correlation analysis of the 116 peptide biomarkers with disease stage and grade and performance of peptide classifiers in detecting NMIBC and MIBC.
View article: Supplementary Table S4 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S4 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S4. Table summarizing the significant biomarkers that were revealed after statistical analysis between recurrent UBC cases (n=109) and negative for recurrence controls (n=316), using Wilcoxon test. The significant bioma…
View article: The Optimized γ-Globin Lentiviral Vector GGHI-mB-3D Leads to Nearly Therapeutic HbF Levels In Vitro in CD34+ Cells from Sickle Cell Disease Patients
The Optimized γ-Globin Lentiviral Vector GGHI-mB-3D Leads to Nearly Therapeutic HbF Levels In Vitro in CD34+ Cells from Sickle Cell Disease Patients Open
We have previously demonstrated that both the original γ-globin lentiviral vector (LV) GGHI and the optimized GGHI-mB-3D LV, carrying the novel regulatory elements of the 3D HPFH-1 enhancer and the 3’ β-globin UTR, can significantly increa…
View article: Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story
Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story Open
Despite the major advances in screening and therapeutic approaches, gynaecological malignancies still present as a leading cause of death among women of reproductive age. Cervical cancer, although largely preventable through vaccination an…
View article: Mimiviruses: Giant viruses with novel and intriguing features (Review)
Mimiviruses: Giant viruses with novel and intriguing features (Review) Open
The Mimivirus is a giant virus that infects amoebae and was long considered to be a bacterium due to its size. The viral particles are composed of a protein capsid of ~500 nm in diameter, which is enclosed in a polysaccharide layer in whic…
View article: 1136 The differential expression of LIMA1/EPLIN in normal and cervical cancer tissues
1136 The differential expression of LIMA1/EPLIN in normal and cervical cancer tissues Open
Introduction/Background* LIMA1 or EPLIN is a cytoskeleton-associated protein involved in cytoskeleton regulation and dynamics, by inhibiting actin filament depolymerization and cross-linking filaments. The role of LIMA1 has been investigat…
View article: 1138 Aberrant expression of enzymes regulating m6A RNA methylation in cervical cancer cell lines, and their implication to cervical cancer
1138 Aberrant expression of enzymes regulating m6A RNA methylation in cervical cancer cell lines, and their implication to cervical cancer Open
Introduction/Background* RNA modifications play a key role in the regulation of gene expression. Among them, N6-methyladenosine (m6A) is the most prevalent mRNA modification. m6A methylation modulates the gene expression by influencing num…
View article: 1129 Downregulation of LIMA1expression induces cancer features in normal cervical keratinocyte HCK1T cells leading to increased migration and invasion
1129 Downregulation of LIMA1expression induces cancer features in normal cervical keratinocyte HCK1T cells leading to increased migration and invasion Open
Introduction/Background* Cervical cancer (CC) remains the fourth most common and lethal cancer type in women; therefore, a comprehensive understanding of the underlying mechanisms and development of novel diagnostic, prognostic and therape…
View article: Metabolic rewiring is associated with HPV-specific profiles in cervical cancer cell lines
Metabolic rewiring is associated with HPV-specific profiles in cervical cancer cell lines Open
Both HPV-positive and HPV-negative cervical cancers are associated with aberrant metabolism, although the oncogenic drivers remain elusive. Here we show the assessment of the metabolomic profiles of four distinct cervical cell lines, a nor…
View article: The EHA Research Roadmap: Anemias
The EHA Research Roadmap: Anemias Open
In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research1 aiming to highlight achievements in the diagnostics and treatment of blood disorders, and to better inform European policy maker…
View article: Recommendations for Pregnancy in Rare Inherited Anemias
Recommendations for Pregnancy in Rare Inherited Anemias Open
Rare inherited anemias are a subset of anemias caused by a genetic defect along one of the several stages of erythropoiesis or in different cellular components that affect red blood cell integrity, and thus its lifespan. Due to their low p…